Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from INCY

Are These 3 Biotech Stocks Good Buys?

Given that the biotech sector is rapidly expanding with robust demand, technology advancements, and government initiatives, fundamentally strong biotech stocks Incyte (INCY), Corcept Therapeutics (CORT), and Entrada Therapeutics (TRDA) look poised to generate significant returns. Hence, these stocks could be solid additions to your portfolio. Read on.

3 Biotech Stocks Poised to Skyrocket

3 Biotech Stocks Poised to Skyrocket

On the backs of successful trials and breakthrough therapies, the biotech market is poised to thrive. Therefore, scooping up the shares of fundamentally sound biotech stocks such as BioMarin Pharmaceutical (BMRN), Incyte Corp. (INCY), and Innoviva (INVA) could be beneficial. Read more….

The 3 Best Biotech Stocks to Buy for Under $100

The 3 Best Biotech Stocks to Buy for Under $100

Despite macroeconomic uncertainties, the biotech industry is anticipated to thrive amid robust demand and lucrative government initiatives. Given the promising prospects of the industry, quality stocks Gilead Sciences (GILD), Incyte (INCY), and Taisho Pharmaceutical (TAIPY) might be wise additions to your portfolio. These stocks are currently trading under $100. Keep…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Low-Volatility Stocks to Invest in Right Now

U.S. GDP declined for the second straight quarter from April to June, adding to the recession concerns. Moreover, considering the lingering macroeconomic headwinds, we think it could be wise to scoop up shares of low-volatility stocks Leidos (LDOS), Incyte (INCY), and The Coca-Cola Company (KO) now. Keep reading….

3 Stocks the World's Greatest Investors Are Buying up Right Now

Skyrocketing inflation, the Fed’s aggressive interest rate hikes, and growing recession fears have kept the stock market under tremendous pressure lately. Amid the market’s downtrend, the world’s renowned investors are scooping up quality stocks Occidental Petroleum (OXY), Amazon.com (AMZN), and Incyte (INCY). Continue reading….

Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?

Image sourced from Shutterstock

3 Bargain Stocks Near 52-Week Lows to Buy and Forget

The lingering inflation and the Fed’s aggressive rate hikes are taking a toll on the market. However, we think it could be wise to buy and hold financially robust bargain stocks Meta Platforms (META), Micron Technology (MU), and Incyte (INCY), which are currently trading near 52-week lows. Keep reading….

inkl

Read news from The Economist, FT, and more,
with one subscription

CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss

CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) for severe alopecia areata (AA). If approved, Olumiant would be the first centrally-authorized oral treatment and first JAK inhibitor for severe AA in the European Union. …

3 Buy-Rated Biotechs to Buy in May

3 Buy-Rated Biotechs to Buy in May

Despite logistical hurdles, the biotech industry is expected to expand solidly in the coming years on lucrative federal investments and strong demand. Therefore, we think it could be wise to bet on the stocks of quality biotech companies Biogen (BIIB), BioNTech (BNTX), and Incyte (INCY). These stocks are rated ‘Buy’…

Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance

Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance

Incyte Corporation's (NASDAQ:INCY) Q1 adjusted EPS reached $0.55, compared to $0.67 posted a year ago. Analysts had estimated $0.68. Sales increased 21% Y/Y to $733.24 million, missing the consensus of $750.66 million. The company's operating expenses increased 22% to $616.69 million, with the cost of sales up 45.8%, R&D costs up 15%,…

5 Outperforming Biotech Stocks with More Room to Run

5 Outperforming Biotech Stocks with More Room to Run

Thanks to the global COVID-19 vaccination drive and inelastic demand for healthcare, biotechnology stocks have been outperforming the broader markets so far this year. Because this trend will likely continue, we think investing in popular biotech stocks Regeneron Pharmaceuticals (REGN), Exelixis (EXEL), Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Incyte Corp.…

Incyte's Ruxolitinib Shows Further Improvement In Facial, Total Body Re-pigmentation At 52 Weeks In Skin Disorder

Incyte's Ruxolitinib Shows Further Improvement In Facial, Total Body Re-pigmentation At 52 Weeks In Skin Disorder

Incyte Corporation (NASDAQ: INCY)

MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland

MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland

FDA Extends Decision Date For Incyte's Ruxolitinib In Vitiligo Skin Disorder

FDA Extends Decision Date For Incyte's Ruxolitinib In Vitiligo Skin Disorder

The FDA has extended the review period for Incyte Corporation's (NASDAQ:INCY) supplemental application for ruxolitinib cream (Opzelura) for vitiligo. The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to July 18 from April 18. The FDA extended the PDUFA action date to review additional data from the ongoing Phase 3…

Get all your
news in one place.

100's of premium titles.
One news app.

Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients

According to a British study, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%. According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial. Results showed that 546 patients…

Expert Ratings For Incyte

Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:

Incyte's Return On Capital Employed Insights

According to Benzinga Pro, during Q4, Incyte (NASDAQ:INCY) earned $563.85 million, a 210.25% increase from the preceding quarter. Incyte also posted a total of $862.85 million in sales, a 6.13% increase since Q3.

Why Are Incyte Shares Trading Lower Today?

Incyte Corporation's (NASDAQ: INCY)

Get all your
news in one place.

100's of premium titles.
One news app.

Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus

Incyte Corporation (NASDAQ: INCY) is

3 Biotech Stocks Poised to Outperform in 2022

With COVID-19 mutating into newer, more transmissible variants, biotechnology stocks have the potential to again outperform as authorities worldwide redouble their efforts at mass vaccinations. So, we think it could be wise to now add quality biotech stocks Vertex Pharmaceuticals (VRTX), BioNTech SE (BNTX), and Incyte (INCY) to one’s watchlist.…

Where Incyte Stands With Analysts

Within the last quarter, Incyte (NASDAQ:INCY) has observed the following analyst ratings:

1 2 3

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Amazon.com Inc.

Gilead Sciences Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

405,553 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play